Nearly 90 percent of patients with an aggressive subtype of non-Hodgkin lymphoma had their cancer go into remission in a small phase 2 clinical trial testing a treatment aimed at making chemotherapy more effective, according to Weill Cornell Medicine and NewYork-Presbyterian investigators.
2023 Biomedical Engineering Symposium Highlights
May 29, 2023
Biomedical Engineering Symposium Showcases Research and Facilitates Collaborations
A two-day intercampus event, the “Biomedical Engineering Symposium: Tools to Transform Discovery & Care,” recently brought together dozens of specialists in the biomedical engineering field recently to share and discuss how this field can be used to improve nearly every aspect of healthcare.
Meeting Co-Chairs, from left, Drs. Marjolein van der Meulen, Susan C. Pannullo, and Olivier Elemento.
Exploring Voice as a Biomarker for Health
April 24, 2023
The Bridge2AI-Voice Consortium, a program based on the NIH-funded study called Voice as a Biomarker of Health that is co-led by experts from Weill Cornell Medicine’s Englander Institute for Precision Medicine (EIPM) and the USF Health Morsani College of Medicine in Tampa, recently held a unique, first-of-its-kind gathering of experts across industries to explore the impact voice can have on health care.
EIPM's First Quarter External Newsletter
April 3, 2023
Dear Friend of the Englander Institute for Precision Medicine,
Welcome to our first quarterly external newsletter of 2023!
Thank you for signing up on our website to receive this newsletter, we hope you enjoy learning more about the important progress we’ve made towards our mission since last year.
EIPM Researcher Receives Grant to Study Prostate Cancer Evolution
March 22, 2023
Dr. Ekta Khurana, an associate professor of physiology and biophysics at Weill Cornell Medicine, has received a 3-year, $1.2 million grant from the United States Department of Defense to investigate how prostate cancer cells evolve to become resistant to hormone-blocking therapy. This work will contribute to further understanding prostate cancer and the development of effective targeted therapies for the disease.
Dr. Omar Abdul-Rahman Named EIPM Director of Clinical Genetics
February 23, 2023
Dr. Omar Abdul-Rahman, a leading specialist in pediatric genetic medicine, has been named chief of the Division of Medical Genetics in the Department of Pediatrics at Weill Cornell Medicine and NewYork-Presbyterian Komansky Children’s Hospital, effective March 1.
February 2023 EIPM Director's Memo
February 1, 2023
Dear Members of the Englander Institute,
We are thrilled to announce that applications are now being accepted for our very popular 6-week Summer Program for high school, college, and grad students, hosted by the EIPM and the Meyer Cancer Center! Students will actively participate in a range of projects related to cancer biology, precision medicine, cancer epidemiology, health disparities, academic research, computational biomedicine, journal clubs, professional development courses and more.
EIPM's Fourth Quarter External Newsletter
January 6, 2023
Dear Friend of the Englander Institute for Precision Medicine,
Welcome to our final quarterly external newsletter of 2022!
January 2023 EIPM Director's Memo
January 2, 2023
Dear Members of the Englander Institute,
As we begin the new year I’d like to thank everyone for their hard work, productivity, and dedication to our mission. It’s a great pleasure to work along side you, and I can hardly wait to see what the new year brings!
Enzyme That Protects Against Viruses Could Fuel Cancer Evolution
December 28, 2022
An enzyme that defends human cells against viruses can help drive cancer evolution towards greater malignancy by causing myriad mutations in cancer cells, according to a study led by investigators at Weill Cornell Medicine. The finding suggests that the enzyme may be a potential target for future cancer treatments.